Cross Shawn 4

What Happened Shawn Cross, Chief Financial Officer of Pacira BioSciences (PCRX), received a grant of 49,091 restricted stock units (RSUs) on February 11, 2026. The filing reports an acquisition price of $0.00 (the grant has no immediate cash cost or proceeds). This is an award/compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-11; filing date (Form 4): 2026-02-13 (filed two days after the grant).
• Amount granted: 49,091 RSUs; reported acquisition price: $0.00; total reported value at grant: $0.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: The RSUs vest in four equal annual installments beginning February 15, 2027, contingent on continuous service; each RSU converts to one share upon vesting.
• No 10b5-1 plan, tax-withholding sale, or late-filing flag noted in the filing summary provided.

Context RSU grants are a form of compensation and typically vest over time, aligning executives' interests with shareholders. Because these RSUs vest in future installments rather than being sold or bought in the market, the grant does not represent an immediate buy or sell signal for investors.